Kedrion S.p.a.
Clinical trials sponsored by Kedrion S.p.a., explained in plain language.
-
New treatment tested for dangerous bleeding in rare disease
Disease control Recruiting nowThis study is testing whether a medication called Coagadex can safely and effectively stop or prevent bleeding in adults with a rare clotting problem caused by light chain amyloidosis. The medication provides concentrated clotting factor to help blood clot properly. Researchers w…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for nerve disease: testing better doses of common treatment
Disease control Recruiting nowThis study aims to find the best dose of a standard immune globulin (IGIV) treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness. Researchers will compare a lower dose (0.5 g/kg) to a standard dose (1.0 g/kg) given e…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New treatment trial aims to boost platelets and stop bleeding in chronic ITP
Disease control Recruiting nowThis study is testing the effectiveness and safety of an intravenous immunoglobulin (IVIg) treatment for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, increasing the risk of bleeding. The main goal is to see if the treat…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC